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Hematopoietic stem cells (HSCs) rely on instructive cues from the bone marrow (BM) niche to maintain their
quiescence and adapt blood production to the organism’s needs. Alterations in the BM niche are commonly
observed in bloodmalignancies and directly contribute to the aberrant function of disease-initiating leukemic
stem cells (LSCs). Here, we review recent insights into the cellular and molecular determinants of the normal
HSC niche and describe how genetic changes in stromal cells and leukemia-induced BM niche remodeling
contribute to blood malignancies. Moreover, we discuss how these findings can be applied to non-cell-
autonomous therapies targeting the LSC niche.HSCs self-renew and differentiate into all the cells of the hemato-
poietic system, and they are responsible for lifelong blood pro-
duction (Orkin and Zon, 2008). Under normal conditions, HSCs
are found in the bone marrow (BM) in specialized niche microen-
vironments that are critical for their maintenance and functional
activity. Stem cell niches were first postulated to exist by Scho-
field in his pioneering review article on spleen colony-forming
units (CFU-S) in the 1970s (Schofield, 1978). Building on these
early observations, technical advancements over the past
several decades have allowed detailed visualization and mecha-
nistic studies of the key cellular and molecular determinants of
the HSC niche. Moreover, the remodeling of the BM microenvi-
ronment has emerged as an important event in the development
of blood malignancies, involved in controlling the maintenance
and activity of disease-initiating LSCs and their progeny. Under-
standing the differences between normal and malignant BM
niches may therefore hold the key to developing non-cell-auton-
omous therapies for a broad range of blood disorders. In this Re-
view, we highlight recent work deciphering the normal HSC
niche, describe the role of these cellular and molecular niche
components in disease settings focusing on myeloid malig-
nancies, review experimental evidence of an active role for the
leukemic BM niche in disease development, and discuss thera-
peutic targeting to abrogate self-reinforcing leukemic niches and
restore normal hematopoiesis.
The HSC Niche: A Puppet Master
The HSC niche is now viewed as a complex ecological system
found at many locations in different bones, and it is composed
of a large number of cell types with specialized functions that
provide distinct chemical signals and physical interactions
essential for HSC maintenance and regulation of blood produc-
tion (Figure 1). The cellular components of the BM niche can be
categorized into two functional types: essential cell types like
endothelial cells (ECs), mesenchymal stromal cells (MSCs),
and megakaryocytes (Megs), which provide close proximity254 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.signals to HSCs; and accessory cell types like osteoblasts
(OBs), specialized macrophages, and nerve cells, which exert
long-range and often indirect influences on HSCs. A number
of the signals provided locally by the BM niche cells are known,
and their roles in controlling HSC function are now well under-
stood (Pietras et al., 2011; Frenette et al., 2013). Secreted fac-
tors like stem cell factor (SCF), transforming growth factor
beta-1 (TGF-b1), platelet factor 4 (PF4 or CXCL4), angiopoietin
1 (ANGPT1), and thrombopoietin (TPO) are all critical enforcers
of HSC quiescence. Alongside the essential chemokine stro-
mal-derived factor 1 (SDF1a or CXCL12) and its C-X-C chemo-
kine receptor type 4 (CXCR4), adhesion molecules such as
vascular cell adhesion protein 1 (VCAM-1), various selectins,
and extracellular matrix (ECM) proteins like fibronectin or hyal-
uronic acid are all essential regulators of HSC homing and
anchoring in the niche. Finally, cell-bound molecules such as
Notch ligands or locally secreted cytokines such as interleukin
7 (IL-7) or erythropoietin (EPO) are important controllers of HSC
proliferation and differentiation activity. In adult bones, HSCs
are essentially kept in the G0 phase of the cell cycle in a stage
of metabolic dormancy or quiescence, which preserves their
function by limiting damage associated with cell replication
(Bakker and Passegue´, 2013). However, quiescent HSCs can
quickly respond to a broad range of niche or systemic signals
by entering the cell cycle and proliferating (Pietras et al.,
2011). These instructive cues are therefore essential for
tailoring HSC differentiation and adjusting blood production to
the needs of the organism. HSCs can also leave the BM niche
upon receiving mobilization signals and enter the bloodstream
to ensure immune surveillance of peripheral tissues (Massberg
et al., 2007) and engraft distant BM sites (Wright et al., 2001).
Thus, HSCs critically depend on short- and long-range instruc-
tive cues from the BM niche for many aspects of their biology,
including cell cycle and trafficking activity, due to the dynamic
regulation of the switch between quiescence/proliferation and
anchoring/mobilization.
Figure 1. Organization of the HSC Niche
(A) Overall anatomy of the marrow cavity depicting the sympathetic innervation and the vasculature and highlighting the interconnection between arteriole and
sinusoid blood vessels. Each of these regions (dotted box) is enriched for a particular subset of perivascular MSCs, which controls a different HSC functional
state. Quiescent HSCs are G0 dormant cells. Active HSCs are cells that have just exited quiescence or are already actively cycling or migrating.
(B) Blow up of the essential (black) and accessory (gray) HSC niche cells with their respective secreted and/or cell-bound factors (color-coded) that regulate HSC
functional states. Dotted circles group cells with either similar origin (i.e., perivascular MSC subsets and differentiating OBCs) or similar function (i.e., specialized
macrophages [Mac] and SNS components). Black arrows highlight MSC progeny that are differentiating into bone-lining OBs and forming the OBCcompartment.
Gray arrows indicate the long-range, indirect effects of several accessory HSC niche cells. CAR, CXCL12bright MSCs; E-Sel, E-selectin; LEP-R, NG2LEP-
R+Nesbright MSCs; NG2, NG2+LEP-RNesdim MSCs; nmSC, non-myelinating Schwann cells; NorE, norepinephrine; OCL, osteoclasts; OPr, osteoprogenitors;
OsM, osteomacs.
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emerged from technical breakthroughs in imaging HSCs in the
marrow cavity, coupled with a series of elegant functional
studies in murine models. Immunofluorescence visualization of
LinCD41CD48CD150+ HSCs in their native BM microenvi-
ronment shows that while present in the OB-rich trabeculated
areas and endosteal bone surfaces, close to 60% of HSCs are
directly associated with the vasculature (Figure 1A) (Kiel et al.,
2005; Kunisaki et al., 2013). The marrow vasculature is essen-
tially composed of a dense network of small arterioles and sinu-
soids that are enriched along the bone surface (Nombela-Arrieta
et al., 2013). These thin-walled blood vessels are made from a
single EC layer and are surrounded by perivascular MSCs andother non-circulating hematopoietic cells such as large mature
Megs. Arterioles branch up and down the endosteal bone sur-
face from large nutrient arteries and connect to sinusoids, which
are then collected into central veins. Both nutrient arteries and
central veins enter and exit the long bones via the same nutrient
foramina, with sympathetic nerve fibers following a similar path
and spreading along the arterioles. The low blood flow of the
arteriole/sinusoid network also limits gas exchange and creates
a relatively hypoxic microenvironment (Spencer et al., 2014). The
marrow cavity is therefore extremely well vascularized and inner-
vated with an immediate access to systemic factors and a quick
ability for HSCs and other hematopoietic cells to enter or leave
the bones through the bloodstream. These key features areCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 255
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most cell types found in close proximity to the vasculature have
HSC-supportive activity (Figure 1B).
Essential Components
Essential HSC niche cells have been identified through genetic
ablation studies in mice in which their specific deletion or
functional inactivation resulted in decreased numbers of HSCs
maintained in the BM niche. These cells share several common
features including direct contact with HSCs and production of
signals important for enforcing HSC quiescence and anchoring
HSCs in the niche. The large functional overlap between these
cells also contributes to the resilience of the HSC niche and ex-
plains in large part the rather limited impact of most genetic abla-
tion studies.
Vascular ECs. ECs are located at the interface between the
bloodstream and the interstitial stromal microenvironment sur-
rounding the blood vessels. ECs are identified via the endothe-
lial-specificmarkersCD31,MECA-32, VE-cadherin, and vascular
endothelial growth factor receptor 2 (VEGFR2) or by their abun-
dant expression of the ECM basal membrane component lami-
nin. They express many HSC-supportive factors including SCF
and CXCL12, various Notch ligands that stimulate HSC self-
renewal expansion (Butler et al., 2010), and other cell-bound
molecules such as the endothelial-leukocyte adhesion molecule
1 (E-selectin), which promotes HSC proliferation (Winkler et al.,
2012). ECs are directly involved in maintaining HSCs in the BM
niche as shownby several studies investigating the consequence
ofTie2-mediated deletion ofScforCxcl12 expression (Ding et al.,
2012; Ding and Morrison, 2013; Greenbaum et al., 2013). TIE2
is the receptor for ANGPT1 and is only expressed by the
vasculature and some hematopoietic cells. ECs have therefore
a widespread role in regulating HSC activity in the adult BM, in
addition to their essential function in specifying and educating
HSCs during fetal development (Orkin and Zon, 2008; Tamplin
et al., 2015).
Perivascular MSCs.MSCs are stem cells for the entire mesen-
chymal lineage, producing bone, cartilage, and fat cells, as well
as various fibroblast-like stromal cells with essential scaffolding
roles in depositing and shaping ECM components. BM MSCs
are rare cells that wrap around arteriole and sinusoid vessels
and are in direct contact with the non-luminal side of ECs. Peri-
vascular BM MSCs may, in fact, share functional properties and
developmental origins with pericytes that are more broadly
found around the smallest blood vessels throughout the body
(Crisan et al., 2008; Armulik et al., 2011). They can be visualized
with a particular nestin (Nes)-GFP transgene (Me´ndez-Ferrer
et al., 2010) and identified via the classical mesenchymal-spe-
cific markers platelet-derived growth factor receptor alpha
(PDGFRA or CD140a), CD51, and Sca-1 (Winkler et al., 2010;
Pinho et al., 2013) or via the expression of the leptin receptor
(LEP-R) (Zhou et al., 2014) and the pericyte marker neuron/glial
antigen 2 (NG2) (Kunisaki et al., 2013). Although there is a signif-
icant functional overlap between MSC populations defined
with thesemarkers in terms of multipotency and self-renewal ca-
pacities, their distribution in the BM cavity and their association
with specific blood vessels is distinct (Frenette et al., 2013; Mor-
rison and Scadden, 2014). While NG2+LEP-RNesdim pericyte-
like MSCs are essentially peri-arteriolar and located close to
the endosteal bone surface, NG2LEP-R+Nesbright reticular-like256 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.MSCs are peri-sinusoidal and located more centrally, away
from the endosteum (Kunisaki et al., 2013). In addition, quiescent
Ki67 HSCs co-localize with peri-arteriolar NG2+ MSCs, while
activated Ki67+ HSCs move toward peri-sinusoidal LEP-R+
MSCs, suggesting a differential involvement of MSC subsets in
enforcing HSC quiescence and promoting HSC proliferation,
respectively. As expected, perivascular MSCs express many
HSC-supportive factors including SCF and CXCL12. In fact,
high expression of Cxcl12 defines a subset of perivascular
MSCs called CXCL12-abundant reticular (CAR) cells, which are
important for controlling HSC proliferation and are likely a more
mature progenitor subset (Sugiyama et al., 2006; Omatsu
et al., 2010). Moreover, perivascular MSCs, like ECs, are directly
involved in maintaining HSCs in the BM niche as shown by a
series of studies investigating the consequence of either Nes-
or Cxcl12-mediated MSC ablation (Me´ndez-Ferrer et al., 2010;
Omatsu et al., 2010) or Lep-R- or Prx1-mediated deletion of
Scf and Cxcl12 expression in MSCs (Ding et al., 2012; Ding
and Morrison, 2013; Greenbaum et al., 2013). Perivascular
MSCs therefore have a more specialized function than ECs
in controlling HSC cell cycle and trafficking activity, eventually
acting through re-localization of activated and/or migrating
HSCs to different MSC subsets with different perivascular
localizations.
Non-circulating mature Megs. Mature Megs are differentiated
hematopoietic cells that are abundant in the BM cavity and other
organs in the body, and they are found transiently associated
with sinusoidal blood vessels for platelet production. They are
identified by their unique large and multinucleated morphology
and by their expression of specific megakaryocytic-markers
including CD41, CXCL4, and von Willenbrand factor (vWF).
Megs secrete many quiescence-enforcing factors including
CXCL4 (Bruns et al., 2014), TGF-b1 (Zhao et al., 2014), and
TPO (Nakamura-Ishizu et al., 2014), as well as signals that acti-
vate HSC proliferation in regenerative stress conditions such
as fibroblast growth factor 1 (FGF1) (Zhao et al., 2014). HSCs
are often found in direct contact of Megs, and results from recent
Cxcl4-mediated ablation studies demonstrate that Megs are
important regulators of HSC cell cycle activity (Kiel et al., 2005;
Bruns et al., 2014; Zhao et al., 2014). Mature Megs therefore
comprise an even more specialized component of the HSC
niche, which tailors HSC cell cycle activity based on demands
and is particularly important in enforcing HSC quiescence.
Accessory Components
Accessory HSC niche cells have been identified through similar
mouse genetic ablation studies but instead of affecting the num-
ber of HSCs maintained in the BM niche, they essentially alter
HSC differentiation potential and trafficking ability. These cells
can be located at a distance from or in close proximity to
HSCs, and they usually impact on HSC function by producing
factors with long-range effects and by influencing the activity
of other BM niche cells.
Differentiating osteoblastic lineage cells. Osteoblastic lineage
cells (OBCs) are an imperfectly defined compartment of MSC
progeny committed to the osteoblastic lineage that comprises
many intermediary stages of differentiation, including immature
osteoprogenitors (OPrs) and mature bone-lining and bone-form-
ing OBs. OBCs still express some MSC markers such as CD51
and the activated leukocyte cell adhesion molecule (ALCAM or
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expression of CD140a and Sca-1 (Nakamura et al., 2010;Winkler
et al., 2010). As such, OBCs express transcription factors spe-
cific to OPr like Runx2 and Osterix (Sp7) and markers of mature
OBs such as osteocalcin. In addition, LinCD45CD51+Sca1
OBCs show a significant overlap with CAR MSCs (Schepers
et al., 2013), which have more restricted differentiation potential
along the adipocytic and osteoblastic lineages and also control
the proliferation of lymphoid and erythroid progenitors (Omatsu
et al., 2010). OBCs can be genetically manipulated via the Sp7
promoter to target MSCs/OPrs and via the Col1-a1 2.3kb
(Col1) promoter-fragment to target mature OBs (Me´ndez-Ferrer
et al., 2015). Differentiating OBCs express many factors impor-
tant for HSC function including CXCL12, SCF, and ANGPT1,
as well as ECM proteins like osteocalcin, collagen 1, and osteo-
pontin (Winkler et al., 2010; Schepers et al., 2013). Mature OBs
were initially proposed to be essential HSC niche cells based
on a positive correlation between OB and immature hematopoi-
etic stem and progenitor cell (HSPC) numbers in two engineered
murine models with more OBs (Calvi et al., 2003; Zhang et al.,
2003). However, additional studies have since refuted this obser-
vation and showed that mature OBs do not directly affect HSC
maintenance in the BM (Frenette et al., 2013). Accordingly,
Sp7- or Col1-mediated deletion of Scf or Cxcl12 expression in
OBCs does not alter HSC numbers but, instead, reduces the
numbers of B lymphoid progenitors (Ding and Morrison, 2013;
Greenbaum et al., 2013). In fact, OBs directly secrete IL-7 and
are important to control B lymphopoiesis (Wu et al., 2008).
OBs also produce EPO and regulate erythropoiesis in response
to hypoxic signals (Rankin et al., 2012). Differentiating OBCs are
therefore emerging as having a dual function in controlling HSC
activity, with themost immature CAR-like OPr subset influencing
HSC proliferation and the most mature OB subset directly
tailoring HSC differentiation along the lymphoid and myeloeryth-
roid lineages.
Specialized macrophages. Bone-associated macrophages
such as osteomacs (OsMs) and bone-resorbing osteoclasts
(OCLs) are another class of hematopoietic cells that has
recently emerged as an important niche component (Morrison
and Scadden, 2014). OCLs are large multinucleated cells that
are positive for tartrate-resistant acid phosphatase (TRAP) ac-
tivity and resorb bone tissue by secreting both acids and
endogenous collagenases. OCLs also regulate MSC differenti-
ation and the production of mature bone-forming OBs through
complex crosstalk mechanisms, thereby indirectly impacting
HSC function. Blockade of OCL function leads to impaired B
lymphopoiesis due to a decreased expression of CXCL12
and IL-7 by improperly maturing OBs (Mansour et al., 2011).
Moreover, complete OCL ablation in osteopetrotic oc/oc
mice results in a dysfunctional HSC niche in which the accu-
mulation of MSCs unable to properly differentiate into OBs
directly impairs HSC homing (Mansour et al., 2012). Similarly,
deletion of OsMs, which are a sub-population of bone-asso-
ciated macrophages expressing F4/80 and CD169, results
in HSC mobilization due to indirect effects on other
BM niche components (Winkler et al., 2010; Chow et al.,
2011). In particular, Nes+ MSCs in OsM-depleted mice
have decreased expression of many HSC-supportive factors,
including CXCL12 and SCF, which could directly contributeto the observed defect in HSC niche anchoring (Chow et al.,
2011). Specialized bone-associated macrophages are there-
fore controlling HSC differentiation potential and trafficking
activity through indirect modulation of MSCs and their OBC
progeny.
Sympathetic nervous system. The sympathetic nervous sys-
tem (SNS) is part of the autonomic nervous system, which
acts largely unconsciously and regulates processes such
as heart rate, digestion, and respiratory rate. However, the
SNS is constantly active at a basal level to maintain homeosta-
sis, and it communicates with the body through release of
catecholamines such as the neurotransmitter norepinephrine
(NorE). NorE binds to b3-adrenergic receptors expressed by
many cells including BM stromal components such as MSCs
and OBs (Asada et al., 2013). In fact, the circadian clock and
rhythmic secretion of NorE lead to rhythmic downregulation
of Cxcl12 expression by BM stromal cells, hence triggering
rhythmic release of HSCs from the BM niche and their mobiliza-
tion to the bloodstream (Me´ndez-Ferrer et al., 2008). Sympa-
thetic nerve fibers are also sheathed by both myelinating and
non-myelinating Schwann cells, which ensure protection and
electrical and chemical isolation between the axons. Non-mye-
linating Schwann cells (nmSCs) are Nes+, similar to some peri-
vascular MSCs, and contribute to keeping HSCs quiescent by
activating latent TGF-b1 found in the surrounding microenvi-
ronment (Yamazaki et al., 2011). The SNS is therefore regu-
lating HSC proliferation and trafficking activity through long-
range signals and indirect modulation of the activity of other
BM niche components.
Advances in Understanding the Human HSC Niche
In contrast to the detailed understanding of the murine HSC
niche, the visualization and mechanistic understanding of the
key cell types and factors controlling human HSC function in
the marrow cavity remains limited mainly due to the difficulty of
accurately modeling these complex relationships in the human
system. Immunohistochemistry studies indicate that 86% of
the primitive CD34+ human HSPCs localize closely to CD271+
alkaline phosphatase (ALP)+ perivascular MSCs that are posi-
tive for CXCL12 (Flores-Figueroa et al., 2012) and that
CD45+CD34+CD38 human HSCs are enriched in the trabecular
areas of the bone (Guezguez et al., 2013). In vitro co-culture
studies have provided further information about the identity of
the human HSC-supportive BM niche cells and the environ-
mental factors regulating human HSC function. Similar to those
in the mouse, ECs, MSCs, and broadly defined OBCs have
all been shown to support the maintenance and/or expansion
of primitive HSPCs in humans (Taichman, 2005). Two recent
studies have highlighted the importance of MSCs by showing
that LinCD45CD51+CD140a+CD146+ enriches for a subset
of Nes+ MSCs with HSC niche activity in human fetal BM (Pinho
et al., 2013) and that LinCD45CD271+CD140a identifies a
population of MSCs in human adult BM that expresses many
HSC-supportive factors and is capable of enhancing the in vivo
repopulating ability of cultured human HSPCs (Li et al., 2014). To
better recapitulate the interactions occurring in human bones,
in vitro co-culture models are now moving toward advanced
3D systems using various mixtures of purified BM niche cells
(Leisten et al., 2012; Sharma et al., 2012; Raic et al., 2014).
Similarly, xenotransplantation approaches are rapidly evolvingCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 257
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cient mice engrafted with ectopic bone-containing human BM
microenvironments (Chen et al., 2012; Groen et al., 2012). These
new approaches, which also allow genetic manipulation of
human niche components, have been successfully used in
studying leukemic cell engraftment and will likely help in better
understanding the human HSC niche. Current studies hint at
many similarities between humans and mice in terms of compo-
sition and function of the HSC niche. However, because human
HSCs are distinct from mouse HSCs for certain aspects of their
biology, the human HSC niche is likely to have unique features
that might not be recapitulated in murine models.
Emerging Questions
The recent identification of novel bone- and fibrosis-producing
MSCs (Kramann et al., 2015) and skeletal stem cell (Worthley
et al., 2015; Chan et al., 2015) populations in mice highlights
the fact that much remains to be learned about the origin and
HSC-supporting function of perivascular MSCs and their deriva-
tives in both mice and humans. In particular, the role of adipo-
cytes still needs to be fully explored given their effect on impair-
ing HSCmaintenance (Naveiras et al., 2009). Future work should
also refine the purification techniques to better separate the
different OBC subsets, as well as arterial versus sinusoidal
ECs, and to enable a better understanding of the dynamic nature
of the HSC niche and its different cellular constituents. Although
some information is currently available about MSC turnover
in vivo (Park et al., 2012), the precise kinetics of MSC differenti-
ation and how fast MSCs and their OBC derivatives are at form-
ing and, eventually, resorbing the HSC niche remain entirely
unknown. In addition, while many environmental cues are known
to trigger a switch from quiescence to proliferation, less is under-
stood about the mechanisms by which quiescence is re-estab-
lished in HSCs and how BM niche cells contribute to this
process. Another largely unexplored aspect of the HSC niche
is the biophysical properties of the BM microenvironment,
including stiffness and ECM composition, and its role in control-
ling HSC function. Similarly, little is known about potential
variability in HSC niche composition depending on anatomical
location and bone types, although the overall structure of the
BM microenvironment is conserved between long bones and
the skull, which is often used for intravital live imaging ap-
proaches (Lo Celso et al., 2009; Lassailly et al., 2013). Finally,
we still need to understand better how these or other BM niche
components contribute to the biology of lymphoid and myeloer-
ythroid progenitors, potentially creating similar and/or distinct
progenitor niches for the development of these lineages in the
marrow cavity.
The LSC Niche: A Partner in Crime
HSCs are constantly exposed to both intrinsic and extrinsic
stresses, which can cause DNA damage and lead to mutations
if not properly resolved (Bakker and Passegue´, 2013). Thesemu-
tations accumulate with age and can result in malignant transfor-
mation (Welch et al., 2012). Many human myeloid malignancies
including myeloproliferative neoplasms (MPNs) like chronic my-
elogenous leukemia (CML) and myelodysplastic syndromes
(MDSs) originate from genetic defects occurring in HSCs (Huntly
and Gilliland, 2005; Woll et al., 2014). These transformed HSCs
maintain the capability to self-renew and give rise to various lin-258 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.eages of blood cells, albeit in a deregulated manner, and behave
as disease-initiating LSCs (Passegue´ et al., 2003). Functionally,
LSCs are characterized by their ability to initiate and serially
propagate diseases upon transplantation, thereby recreating
the primary malignancy and its full heterogeneity in recipient
mice. Inmore aggressive diseases, such as acutemyeloid leuke-
mia (AML) and blast crisis CML (BC-CML), LSCs are no longer
restricted to the HSC compartment and can also emerge from
transformed progenitors (Eppert et al., 2011; Goardon et al.,
2011). For instance, in both human BC-CML and in an MLL-
AF9-driven syngeneic murine AML transplantation model, clonal
evolution and stabilization of nuclear b-catenin can transform
committed granulocyte-macrophage progenitors (GMPs) into
LSCs that have reacquired the ability to self-renew and propa-
gate the leukemia (Jamieson et al., 2004; Krivtsov et al., 2006;
Wang et al., 2010). Hence, LSCs can have diverse cells of origin
and even evolve from HSCs to myeloid progenitors in the course
of the disease.
Genetic changes are well-documented in myeloid malig-
nancies and involve mutations in signaling molecules such as
JAK2, RAS, FLT3, or KIT (Milosevic and Kralovics, 2013).
These genetic lesions provide important cell-autonomous
growth signals to leukemic cells but also alter how LSCs and
their progeny sense environmental signals. Building on the
early observations of altered adhesion properties in human
CML progenitors (Gordon et al., 1987), more recent intravital
imaging approaches have shown that leukemic cells highjack
normal BM vascular niche spaces by exploiting signals such
as CXCL12 and E-selectin that are important for the homing
of healthy HSCs (Sipkins et al., 2005). In addition, LSCs are
less dependent than healthy HSCs on certain niche signals
for their survival, proliferation, and anchoring in the niche.
LSCs in murine models of both CML and AML diseases
become insensitive to Notch and TGF-b-mediated environ-
mental signals (Santaguida et al., 2009; Krause et al., 2013),
which normally limit HSC expansion and myeloid differentia-
tion. LSCs are also more dependent on CD44 extracellular
anchoring and on various selectins and their ligands for hom-
ing and engraftment in the marrow cavity compared to normal
HSCs, as shown in both a syngeneic murine CML transplanta-
tion model (Krause et al., 2006, 2014) and with human AML
xenograft transplantation (Jin et al., 2006). In addition, LSCs
in the syngeneic murine MLL-AF9 AML transplantation model
display less dependency on Wnt-derived signals for localiza-
tion to the marrow compared to normal HSCs (Lane et al.,
2011). These examples clearly illustrate the deranged percep-
tion of the BM microenvironment by LSCs and their progeny,
which is a critical concept in understanding how leukemic he-
matopoiesis can get a stronghold in the BM niche at the
expense of normal hematopoiesis. In addition, it has recently
become clear that leukemic hematopoiesis directly remodels
the BM niche into a self-reinforcing malignant BM niche that
supports disease development at the expense of normal
hematopoiesis. Furthermore, striking observations in murine
models have shown that genetic lesions directly in BM niche
cells could contribute to or even initiate myeloid malignancies.
These two modes of disease initiation are not mutually exclu-
sive as demonstrated by the range of crosstalk and common
self-reinforcing loops found in both situations, and they can
Figure 2. Models of Disease Initiation
The majority of myeloid malignancies are caused by genetic lesions (stars) occurring in hematopoietic cells, which lead to BM niche remodeling and formation of
LSCs with deranged perception of the microenvironment. Genetic lesions can also occur in stromal cells and lead to myeloid malignancies with predisposition to
secondary mutations in hematopoietic cells. These twomodes of disease initiation are not mutually exclusive; they share several commonmechanisms and self-
reinforcing loops including deregulated Notch/Wnt signaling and increased production of pro-inflammatory cytokines. Congenital lesions present in both he-
matopoietic and stromal cells are also observed in myeloid malignancies and likely synergize as well as predispose cells toward additional transforming lesions
and more aggressive diseases. Arrows indicate the directionality of these events.
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forming lesions and more aggressive diseases (Figure 2).
Niche as an Initiator of Disease
The first evidence supporting the concept that transforming non-
cell-autonomous genetic changes could contribute to MPN-like
diseases came from amurine study showing that deletions of the
signaling molecule inhibitor of NF-kB, I kappa B alpha (IkBa), in
the liver leads to the development of non-transplantable MPN-
like diseases (Rupec et al., 2005). This is due to constitutive
expression of the Notch ligand Jagged-1 by IkBa-deficient hepa-
tocytes, which directly drives the aberrant overproduction of
myeloid cells. In two subsequent landmark studies published
in 2007, Walkley and colleagues directly demonstrated the
importance of genetic BM niche changes in the development
of myeloid disorders (Walkley et al., 2007a, 2007b). While Mx1-
Cre-mediated deletion of the retinoblastoma (Rb) gene in both
hematopoietic and stromal elements leads to a widespread
MPN-like disease with splenomegaly, mobilization of cells from
the BM, and eventual loss of HSCs, its sole inactivation in neither
hematopoietic cells nor stromal elements, including BM nichecells, in reciprocal transplantation approaches results in myeloid
disorders (Walkley et al., 2007a). In addition, only transplantation
of Rb-deleted myeloid cells into Rb-deficient, but not wild-type,
mice induces the MPN-like disease, thus confirming the depen-
dency of genetically altered myeloid cells on a transformed BM
microenvironment. Similarly, while constitutive deletion of the
retinoic acid receptor gamma (Rarg) results in the development
of age-related MPN-like diseases, only transplantation of nor-
mal hematopoietic cells into Rarg-deficient mice, and not trans-
plantation of Rarg-deficient hematopoietic cells into wild-type
mice, is able to recreate the myeloid condition (Walkley et al.,
2007b). Along the same lines, MMTV-mediated deletion of the
E3-ubiquitin ligase and canonical Notch ligand regulator mind
bomb 1 (Mib1) in stromal elements causes a MPN-like disease
that is independent of Mib1 status in the hematopoietic com-
partment and can be fully reversed by constitutive activation
of Notch signaling in the microenvironment (Kim et al., 2008).
Together, these studies highlight the role of non-hematopoietic
BM stromal elements in disease initiation, and two subse-
quent studies hint at MSCs and OBCs as being key players inCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 259
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Dicer1 gene in MSCs/OPrs is sufficient to drive the development
of an MDS-like disease with sporadic transformation to AML,
which can be fully reverted upon transplantation into wild-type
mice (Raaijmakers et al., 2010). Loss of Dicer1 in MSCs/OPrs
leads to reduced expression of the ribosome maturation protein
Sbds gene, which is mutated in human Shwachman-Bodian-
Diamond syndrome, a congenital BM failure disease with known
leukemic predisposition. Similarly, Col1-mediated expression of
stabilized nuclear b-catenin and constitutive activation of the
Wnt pathway in OBCs is sufficient to drive the development of
a transplantable AML-like disease with common chromosomal
aberrations (Kode et al., 2014). Activated b-catenin stimulates
expression of the Notch ligand Jagged-1 by mature OBs, which
in turn leads to aberrant activation of Notch signaling in hemato-
poietic cells and the observed AML-like condition. Another
recent study suggests that ECs can also play a direct role in dis-
ease initiation. Tie2-mediated deletion of theRbpj (also known as
Cbf1) gene, a non-redundant downstream effector of the canon-
ical Notch signaling pathway, in ECs is sufficient to cause a fatal
MPN-like disease (Wang et al., 2014). Loss of Notch signaling in
ECs upregulates miR-155, which directly targets the NF-kB in-
hibitor kB-Ras1 and activates NF-kB, thereby increasing their
production of pro-inflammatory cytokines including G-CSF and
tumor necrosis factor alpha (TNFa). This pro-inflammatory
milieu, in turn, directly drives an MPN-like disease condition.
Together, these studies in murine models demonstrate a direct
causal role for several HSC niche components (i.e., MSCs,
OBCs and ECs) in the development of a broad range of myeloid
diseases and identify deregulated Notch andWnt signaling path-
ways, as well as increased production of pro-inflammatory cyto-
kines, as commonly altered mechanisms in BM stromal ele-
ments that drive aberrant production of myeloid cells (Figure 2).
These findings beg the question of whether BM niche changes
are also important for disease initiation in humans. The evidence
is so far limited to correlative data obtained with subject sam-
ples. Consistent with a model of increased b-catenin in OBCs
driving Notch signaling in human AML cells, 38.3% of a cohort
of over 80 subjects with MDS, AML, or MDS that progressed
to AML had BM biopsies showing increased nuclear b-catenin
in Runx2-expressing OBCs associated with increased Notch ac-
tivity in CD34+ HSPCs (Kode et al., 2014). In support of a role for
stromal upregulation of miR-155 in human MPNs, a significant
overexpression of miR-155 was observed in BM aspirates from
primary myelofibrosis (PMF) subjects (Wang et al., 2014). These
data suggest that stromal genetic changes known to drive
myeloid disorders in mice are also found in human tissues and
could similarly contribute to disease development. Other correl-
ative and still controversial evidence includes the fact that stro-
mal cell populations isolated from individuals withmyeloidmalig-
nancies can carry genetic abnormalities that are different from
the driver mutation or mutations in the leukemic clone (Blau
et al., 2007; Kastrinaki et al., 2013). One important caveat with
these studies is that they were performed with serially expanded
cells, which could therefore have acquired new genetic abnor-
malities as the direct consequence of the ex vivo culture. Howev-
er, these results support the idea that genetic changes could
independently occur in BM niche cells during the course of the
disease. In addition, subjects undergoing allogeneic stem cell260 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.transplantations (SCTs) can develop a rare donor-derived leuke-
mia that is distinct from classical recipient disease relapse (Wise-
man, 2011). This phenomenon also supports the idea that an
altered BM stromal compartment could directly contribute to
and/or drive the development of a new leukemia in these sub-
jects, although it remains to be determined whether the stromal
changes are inherent abnormalities or result from the treatments
received before SCT. Nevertheless, it is tempting to speculate
that new genetic lesions could be acquired over time in HSC
niche components (i.e., MSCs, OBCs and ECs) and directly
contribute to the development of human myeloid diseases.
Diseases as an Initiator of Niche Changes
Ample experimental evidence in both humans and mice sup-
ports the opposite concept that malignancies resulting from
transforming genetic changes in hematopoietic cells cause a re-
modeling of the BM niche, which then contributes to disease
progression. Many studies in the past several decades have
described morphological and functional BM stromal changes
in subjects with various hematologic conditions, including
PMF, MDS, and AML. Structural changes in the BM cavity due
to impaired angiogenesis and/or bone loss are now well docu-
mented in both AML and MDS (Du¨hrsen and Hossfeld, 1996).
In PMF, the degree of collagen fiber deposition and ECM remod-
eling is also directly correlated with overall subject survival (Per-
eira et al., 1990). In MDS, subject-derived stromal cells appear
qualitatively different in their ability to support blast cell colonies
and impaired in their ability to maintain long-term cultures of
CD34+ HSPCs (Gida´li et al., 1996; Aizawa et al., 1999), although
these results are still somewhat controversial (Kastrinaki et al.,
2013). Reduced contact inhibition in vitro, impaired ability to
maintain hematopoietic differentiation, and increased osteo-
blastic lineage gene expression are also aberrant features of
stromal cells derived from pediatric MDS subjects (Borojevic
et al., 2004). In addition, tissue sections of MDS subjects show
abnormally high numbers of perivascular ALP+CD271+ MSCs
expressing CXLC12 (Flores-Figueroa et al., 2012), which could
directly contribute to the aberrant BM retention of HSPCs in
this disease. In contrast, BM-derived MSCs from AML subjects
have decreased production of CXCL12 (Ge et al., 2011), which
could also contribute to the impaired maintenance of healthy
HSCs observed in this disease. Illustrating the crosstalk between
leukemic cells and stromal elements, AML cells co-cultured with
ECs produce a range of pro-inflammatory cytokines including
TNFa, interleukin 6 (IL-6), and interleukin 1 (IL-1), which induce
ECs to secrete the myeloid growth factors G-CSF and granulo-
cyte/macrophage colony stimulating factor (GM-CSF). This,
in turn, stimulates the growth of the leukemic cells and creates
a feedforward mechanism promoting disease development
(Griffin et al., 1987). The existence of such self-reinforcing mech-
anisms hints at leukemia-induced BM niche remodeling as a
mechanism for disease progression, an idea that is directly sup-
ported by recent live imaging and xenograft transplantation data.
Key studies from the mid-2000s have visualized the engraftment
of human leukemic cells in immunodeficient mice and have
shown the formation of specialized malignant niches that
directly impair healthy HSC function due to overproduction of
SCF (Sipkins et al., 2005; Colmone et al., 2008). Recently, human
MDS cells were shown to directly rely on deregulated signals
provided by their malignant BM niche, including factors such
Figure 3. Self-Reinforcing Malignant BM Niches
Mechanisms identified in the indicated murine models, which create a self-reinforcing malignant BM niche promoting disease maintenance at the expense of
normal hematopoiesis. Several key features have emerged as common themes from these analyses and include (1) altered MSC growth and differentiation with
eventual fibrosis, (2) elaboration of pro-inflammatory signals, and (3) decreased production of HSC-supportive factors by stromal cells.
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regulators of fibrosis, to efficiently engraft immunodeficient
mice (Medyouf et al., 2014). Furthermore, after exposure to
MDS cells, normal BM stromal cells adopt a phenotype resem-
bling that of the malignant niche including LIF upregulation
(Medyouf et al., 2014). Together, these human data argue that
malignancies invariably alter the function of the BM niche in
ways that favor disease development and impair normal hema-
topoiesis. Recent studies in murine models have expanded
upon these findings and provide novel mechanistic insights
into the formation and function of such self-reinforcing malignant
niches (Figure 3).
Fibrosis of themalignant niche.CML is the humanmyeloidma-
lignancy best studied in mice for its remodeling effect on BM
stromal cells. CML cells produce G-CSF that decreases expres-
sion of CXCL12 by BM stromal cells and directly impairs normal
HSC maintenance in an inducible BCR/ABL transgenic model
(Zhang et al., 2012). In a syngeneic BCR/ABL transplantation
model, CML cells also induce BM stromal cells to secrete
platelet growth factor (PLGF), which in turn enhances CML cell
proliferation in a self-reinforcing loop (Schmidt et al., 2011). Us-
ing the inducible BCR/ABL transgenic model, our group recently
identified OBCs as the key HSC niche component directly re-
modeled by CML cells (Schepers et al., 2013). We show that
CML cells stimulate MSCs to proliferate and adopt an abnormal
differentiation program resulting in the overproduction of func-
tionally altered OBCs, which accumulate in the BM cavity as
inflammatory myelofibrotic cells. We find a role for TPO, the che-
mokine (C-Cmotif) ligand 3 (CCL3 orMIP-1a), and direct cell-cell
interactions between CML myeloid cells and MSCs in driving
OBC expansion, and a role for changes in TGF-b, Notch, and
pro-inflammatory signaling activity in remodeling OBCs into
myelofibrotic cells. In turn, we show that myelofibrotic OBCs
have decreased expression of many HSC retention factors,
including CXCL12, and a compromised ability tomaintain normalHSCs. In contrast, LSCs are not affected by this malignant re-
modeling of the niche, likely due to their deranged perception
of the BM microenvironment (Krause et al., 2006, 2014). Myelo-
fibrotic OBCs also express pro-inflammatory cytokines (i.e., IL-1
and TNFa), which likely amplify disease development and aber-
rant myeloid cell production. Together, these studies demon-
strate that CML development is associated with the formation
of a self-reinforcing fibrotic malignant niche that favors LSCs
and disease development at the expense of healthy HSCs and
normal hematopoiesis. This likely contributes to the clonal domi-
nance of certain LSCs in MPNs that are relatively unfit compared
to normal HSCs (Kent et al., 2013) and do not have a strong driver
mutation directly providing increased competiveness (Li et al.,
2013).
Neuropathy of the malignant niche. Two recent studies using a
knockin Jak2V617F MPN mouse model (Arranz et al., 2014) and
the syngeneic MLL-AF9 AML transplantation approach (Hanoun
et al., 2014) show that leukemic cells can also damage nerve
cells. In both cases, disease development creates neuropathic
changes in the BM niche, which affect the activity of perivascular
MSCs and alter the function of the HSC niche. Interestingly, IL-1-
mediated damage to nerve fibers and nmSCs in Jak2V617F MPN
mice leads to a loss of Nes+ MSCs and an accelerated MPN
phenotype that can be reversed by treatment with 4-methycate-
chol, a neuroprotective drug that signals through b3-adrenergic
receptors (Arranz et al., 2014). Furthermore Jak2V617FMPNmice
develop BM fibrosis despite a reduction in size of the MSC
compartment and the loss of Nes+ MSCs. In the MLL-AF9 AML
transplantation model, in contrast, leukemic cells cause a loss
of peri-arteriolar NG2+ MSCs and nerve fibers, which then leads
to the expansion of an abnormal population of Nes+ MSCs with
skewed osteoblastic differentiation and downregulated expres-
sion of many HSC retention factors, including CXCL12 and
SCF, but no detectable BM fibrosis (Hanoun et al., 2014). These
changes cooperate in promoting AML development and loss ofCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 261
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Together, these studies indicate that leukemia-induced neurop-
athy also promotes the development of a self-reinforcing malig-
nant niche that also favors disease development at the expense
of normal HSCmaintenance. However, the relationship between
such leukemia-induced neuropathy and the formation of a
fibrotic malignant niche is still unexplored.
Emerging Questions
Many aspects of the contribution of the BMmicroenvironment to
myeloid malignancies remain to be investigated. In particular,
whether LSCs reside in specific niches that are directly instruct-
ing and/or maintaining them is still an open question. It is also
currently unknown whether differences in the cell of origin (i.e.,
HSCs versus progenitors) influence where LSCs home and
interact with specific BM niche components. However, what
has clearly emerged from current studies in murine models and
correlative evidence in humansubject samples is thatBMstromal
changes and the formation of a self-reinforcingmalignant niche is
more than a mere bystander effect of disease development and
can directly contribute to myeloid malignancies. A further under-
standing of this process in human diseases will require taking
advantage of the aforementioned 3D co-culture systems and hu-
manized xenograft models to dissect the crosstalk between
leukemic cells and theBMmicroenvironment. These approaches
will be particularly useful to investigate the exact contribution to
human diseases of genetic changes occurring in BM niche cells
and the translational relevance of the current observations inmu-
rine models. Much work also needs to be done in understanding
the mechanisms driving the formation and aberrant function of
the malignant BM niche in human diseases. Several key features
have now emerged as common themes frommurine studies and
include the following: (1) altered MSC growth and differentiation
as the most widespread consequence of disease development;
(2) elaboration of pro-inflammatory signals such as TNFa, IL-1,
and IL-6, which help drivemyeloidmalignancies and BMfibrosis;
and (3) decreased production of HSC-supportive factors such as
CXCL12, SCF, and ANGPT1 by stromal cells, which harms
healthy HSCs and favors LSCs. One of the most exciting ques-
tions is to address whether these recurrent themes are also
important, and potentially targetable, features of malignant niche
establishment in human diseases. It will also be interesting to test
whether early detection of deranged niche signals, including
inflammatory gene activation in BM niche cells and changes in
production of niche-associated factors, have a prognostic value.
Finally, we still need to better understand the connection be-
tween the different perivascular MSC subsets and their OBC
derivatives in driving BM fibrosis. In this context, the recent iden-
tification of Gli1+ MSCs as the general origin of organ fibrosis
(Kramann et al., 2015) should help in identifying the source of
BM fibrosis in myeloid malignancies.
Targeting the LSC Niche: Non-Cell-Autonomous
Treatment Strategies
The recent identification of many driver mutations and the devel-
opment of drugs targeting these deregulated signaling pathways
have had dramatic success in treating subjects with myeloid ma-
lignancies. In the case of CML, BCR/ABL kinase inhibitors have
completely changed the landscape of clinical outcomes, leading
to longer subject survival and deeper remissions (Jabbour et al.,262 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.2013). There has also been success in targeting JAK2 mutations
in MPNs as well as FLT3 activation in AMLs (Verstovsek et al.,
2012; Jabbour et al., 2013). Even given these recent advance-
ments, significant areas of need remain for the treatment of
myeloid malignancies. These include treatment of subjects
without known driver mutations or for whom no drugs are
currently available that target their driver mutations, as well as
treatment of elderly subjects who are not eligible for intense
chemotherapyor curativeSCTapproaches. Theappeal of target-
ing deranged BM microenvironments fits well with these clinical
needs. It represents a non-cell-autonomous treatment strategy
that could be applied to a broad range of subjects with various
types of malignancies and underlying driver mutations. It could
be away to preserve normal HSCs anddisfavor LSCs, thus deep-
eningclinical remissions, and it could easily beusedasanadjunct
therapy alongside drugs directly targeting drivermutations to aim
for curative treatment. Recent discoveries have identified a series
of exciting novel features of the LSC niche that could be targeted
to abrogate the self-reinforcing malignant BMmicroenvironment
and restore normal hematopoiesis. Some strategies like uncou-
pling LSCs and leukemic cells from their protective niches have
already been tested in the clinic and are at various stages of
drug development. Other strategies like targeting the MSC re-
modeling and inflammatory microenvironment are very prom-
ising but remain so far mainly at pre-clinical stages.
Uncoupling LeukemicCells fromTheir Protective Niches
Targeting factors thatmaintainminimal residual disease (MRD) in
the BM niche to draw remaining LSCs and their progeny out of
their protected microenvironment and enhance their killing has
caught considerable interest over the past decade (Nair et al.,
2010). Leukemic cells co-cultured with BM stromal cells are
protected from drug-induced killing via stromal-mediated mech-
anisms involving prevention of apoptosis and induction of quies-
cence in LSCs and their progeny. Pre-clinical work in human
settings and murine models has demonstrated the effectiveness
of blocking the CXCL12-CXCR4 chemokine axis and targeting
the adhesionmolecules CD44 and VCAM-1 to dislodge leukemic
cells from their protective BM niches. Overexpression of CXCR4
on LSCs and their progeny is one of best described mechanisms
promoting the BM anchoring and quiescence of leukemic cells
via its interaction with CXCL12, hence impairing the cytotoxic
effects of various treatment modalities including BCR/ABL
inhibitors in CML and Flt3 inhibitors in AML (Jin et al., 2008;
Zeng et al., 2009; Nervi et al., 2009). Testing in xenograft models
has shown that blocking CXCR4 could mobilize leukemic cells
away from their BM stromal niches, leading to better in vivo
disease eradication (Nervi et al., 2009; Weisberg et al., 2012).
Efficient drugs for manipulating the CXCL12-CXCR4 axis
have existed for years, including the FDA-approved Plerixafor
(AMD3100) that is routinely used in clinical settings for mobilizing
normal HSCs. A phase I/II clinical trial was conducted to test the
safety of combining Plerixafor with cytotoxic chemotherapy in
subjects with relapsed AML, and it was recently reported as a
safe strategy with beneficial clinical outcomes (Uy et al., 2012).
Additional clinical trials are currently ongoing using Plerixafor
or other drugs targeting the CXCL12-CXCR4 axis, alone or in
combination with other mobilizing agents such as G-CSF in
order to sensitize LSCs to conventional chemotherapies both
as front-line therapy for new AML subjects and as second-line
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more dependent on the hyaluronic acid receptor CD44 for their
anchoring in the BM niche than normal HSCs (Jin et al., 2006;
Krause et al., 2006; 2014), which makes CD44 an exciting target
to dislodge leukemic cells from their niche. Because drugs to
block CD44 already exist, including the FDA-approved anti-
CD44v6 monoclonal antibody Bivatuzumab currently used for
clinical trials in solid tumors, it will be exciting to see the potential
of this strategy in myeloid malignancies, especially for subjects
with MRD or relapsed disease. Finally, VCAM-1 engagement of
the a4b1-integrin very large antigen 4 complex (VLA4) is an
emergingmechanismmediating the crosstalk between leukemic
cells and BM stromal cells that promotes chemoresistance (Ja-
camo et al., 2014). This interaction can be blocked with the
FDA-approvedmonoclonal antibody Natalizumab, which targets
both a4 and aE integrins and is currently used for the treatment
of relapsing multiple sclerosis and inflammatory bowel disease.
A small molecule specifically targeting VCAM-1 has recently
been developed (Hsieh et al., 2014) and would be the ideal
drug for testing in myeloid malignancies.
Targeting MSC Remodeling and the Inflammatory
Microenvironment
BMstromal remodeling throughderegulatedgrowth anddifferen-
tiation of MSCs has emerged as a key theme in the development
of myeloid malignancies. In human MPNs, this results in myelofi-
brosis, which ultimately culminates in the development of PMF
diseases but also contributes to the pathogenesis of other
MPNs as exemplified by work in murine models (Abdel-Wahab
and Levine, 2009). Strategies aimed at preventing the develop-
ment of a fibrotic niche and its deleterious consequence for the
maintenance of normal HSCs (Schepers et al., 2013) could help
restore themarrow’s ability to support healthy HSCs and the pro-
duction of normal blood cells. Currently there are no FDA-
approved therapies specifically targeting the fibrotic BM niche,
although reversal of myelofibrosis is a clinically achievable goal
as shown in CML subjects upon BCR/ABL inhibition (Thiele and
Kvasnicka, 2006) or in PMF subjects upon SCT (Daly et al.,
2003). Several agents proposed to target the microenvironment,
including immunomodulatory drugs such as Thalidomide and
Lenalidomide, proteasome inhibitors such as Bortezomib, and
VEGF-targeting drugs such as Sunitinib and Bevacizumab,
have been tested in subsets of PMF subjects. However, these
clinical trials have hadmixed results and severe tolerability issues
(Rambaldi et al., 2008). Considering the importance of TNFa, IL-1,
and IL-6 in driving the fibrotic BM niche remodeling (Schepers
et al., 2013) and CML development (Reynaud et al., 2011) in
murinemodels, it will be very interesting to test theeffect of block-
ing these specific pro-inflammatory cytokines with the various
suppressing, neutralizing, and/or antagonizing antibodies that
are currently available for clinical use. Their efficacy at treating
auto-inflammatory conditions such as secondary hemophago-
cytic lymphohistiocytosis and rheumatoid arthritis shows that tar-
geting a single cytokine in a complex inflammatory process can
provide significant clinical benefit. It will also be exciting to test
whether any of the various FDA-approved bone remodeling
agents such as bisphosphonates currently used for osteoporosis
andasanadjunct inmultiplemyeloma treatmentareefficaciousat
blocking the fibrotic remodeling of the MSC/OBC compartment.
In murine models of MPN and AML, disease development isalso accompanied by SNS neuropathy, which directly alters
MSC growth and differentiation and thereby remodels the BM
niche. Strategies aimed either at directly protecting these nerve
cells or at preserving their action on perivascular MSCs (Arranz
et al., 2014;Hanoun et al., 2014) could also help support the func-
tion of healthy HSCs and maintain production of normal blood
cells. The fact that the clinically approved b3-adrenergic agonist
Mirabegron delays disease onset and improves several MPN-
associated features in the Jak2V617F murine MPN model (Arranz
et al., 2014) reflects the potential of such therapies for human
treatment and provides another exciting path forward.
Emerging Questions
The lack of reliance on a particular driver mutation and the wide
applicability to various disease types makes targeting the malig-
nant BM niche a worthy endeavor. Despite this, many questions
remain regarding the therapeutic benefits of such non-cell-
autonomous strategies. Further testing of drugs targeting the
aberrant homing and adhesion of leukemic cells will demonstrate
whether pushing LSCs and their progeny out of hiding in pro-
tected BM niches is a promising approach to prevent disease
relapse. Time will also tell whether this strategy has any un-
wanted long-term effects on the maintenance of healthy HSCs.
Developing novel approaches to antagonize the soluble factors
that promote malignant niche formation also has therapeutic po-
tential. Strategies include IL-1 and IL-6 blocking therapies, which
are available in the clinic but not yet used in myeloid malig-
nancies, as well as the blockade of novel targets that are impor-
tant for BM stromal remodeling and myelofibrosis development,
such as TPO andMIP-1a. Moreover, establishing newmodalities
to directly block the cellular changes occurring in the malignant
BM niche, including aberrant MSC differentiation into fibrotic tis-
sue and neuropathy-driven MSC alterations, also has great ther-
apeutic potential. Strategies will include using established bone
remodeling agents and b-adrenergic modulators that are avail-
able but have not yet been tested in myeloid malignancies. Alto-
gether, this will build an arsenal of new therapeutic compounds
for targeting themalignant BM niche and restoring normal hema-
topoiesis. Finally, while transformed HSCs and progenitor cells
can be efficiently replaced through SCT approaches, defective
BM stromal function is usually not corrected and can potentially
impair the activity of newly transplanted HSCs. The same strate-
gies could therefore be used as preconditioning regimens for
SCT in order to restore the marrow’s ability to support healthy
HSC function and ensure that the BM microenvironment prefer-
entially supports normal hematopoiesis over potential remaining
LSCs. This could help achieve and maintain deeper clinical
remissions in pre- and post-transplantation settings. These
exciting new clinical directions illustrate how gathering comple-
mentary basic and translational research in deciphering the fea-
tures of the normal HSC niche, investigating the deregulated
properties of the malignant niches, and testing the efficacy of
new drugs targeting these deregulated microenvironments are
bringing us closer to the goal of achieving curative treatments
for a broad range of human blood malignancies.AUTHOR CONTRIBUTIONS
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